• Global drug spending to hit $1.4 trillion in 2020: IMS

    Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will


  • Lessons from Australia and China’s Healthcare Cooperation: What Can Canadian Firms Learn?

    NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit


  • South Korea's Genexine expands into China in Tasgen deal for up to $100M

    South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i


Investment Opportunities

Opportunities

Potash in another mining friendly region other than Saskatchewan

With the junior mining sector struggling in the past few years, it is difficult for inv... Full Story

The hidden gems in CSE

Breaking News

Tencent Leads $200 Million Round in Haodaifu, a Mobile Healthcare App

Tencent Holdings, China's largest internet services company, led a $200 million series D round in Haodaifu Online, a large mobile healthcare app. Founded in 2006, Haodaifu, which ...

Fosun CEO resigns as new team named

JHL Starts European Trial of MabThera/RituxanBiosimilar for RA

Gene Quantum (Suzhou) Raises $5.8 Million in A Round for ADC Drugs

Chinese drug approval boosts AstraZeneca's lung cancer hopes

Select Companies

Replicel Life Sciences Inc

Replicel Life Sciences Inc is a clinical stage bio-pharmaceutical company engaged in developing a...

Imprimis Pharmaceuticals Inc

Imprimis Pharmaceuticals is a specialty pharmaceutical company focused on the development and com...

Diamedica Inc

Diamedica Inc is a development stage biopharmaceutical company. The Company is engaged in the dis...

Experts Column

Top 10 Developments that Investors should pay extra attention in the new year

Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...

China could boost growth with supply, property reforms, tax cuts, HSBC says

China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...

Here’s how to play Chinese stocks in 2016?

Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...

G-20 sticks to 2% growth goal despite headwinds

The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...

Why isn't the yuan rising despite IMF support?

The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...

Press Release

CohBar, Inc.’s CEO Simon Allen to Present at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York

, a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will ...

Naturally Splendid to Appear in the Canadian Cannabis Investor Magazine and on the U.S. Cannabis Investor Webcast

is pleased to announce that it will be featured in the inaugural April issue of the new Canadian CANNAINVESTOR Magazine. To view the Company’s feature article in the new Canadian CA...

RepliCel's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems

 ("RepliCel" or the "Company") is pleased to report compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use of RepliCel&#...

DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017

Imprimis Pharmaceuticals to Raise $3.1 Million in Registered Direct Offering

CohBar, Inc. Announces Fourth Quarter 2016 Financial Results

Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results

Peer-Reviewed Paper Demonstrates the Benefits of Dropless Cataract Surgery®

Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities

Daily Top Performing Life Science Stocks
         Company Name Symbol Price Change Vol(k) Day's Range Contact
1 Conatus Pharmaceuticals Inc NASDAQ:CNAT 5.920
0.900 (17.93%)
2135309 5.01 - 5.99
2 Diamedica Inc TSXV:DMA 0.270
0.030 (12.50%)
303501 0.25 - 0.28
3 TrovaGene Inc NASDAQ:TROV 1.150
0.100 (9.52%)
175489 1.05 - 1.15
4 Heska Corp NASDAQ:HSKA 102.750
6.990 (7.30%)
432292 100.36 - 104.90
5 Tenax Therapeutics Inc NASDAQ:TENX 0.541
0.036 (7.17%)
605134 0.5000 - 0.5470
6 Imprimis Pharmaceuticals Inc NASDAQ:IMMY 4.220
0.230 (5.76%)
687652 4.02 - 4.39
7 InspireMD Inc NYSE MKT:NSPR 1.010
0.060 (5.76%)
1721271 0.93 - 1.05
8 DelMar Pharmaceuticals Inc NASDAQ:DMPI 4.310
0.220 (5.38%)
45621 4.17 - 4.55
9 AEterna Zentaris Inc NASDAQ:AEZS 3.050
0.150 (5.17%)
493408 2.95 - 3.25
10 Pernix Therapeutics Holdings Inc NASDAQ:PTX 3.700
0.170 (4.82%)
252899 3.42 - 3.71
11 Acasti Pharma Inc NASDAQ:ACST 1.320
0.060 (4.76%)
1094249 1.31 - 1.65
12 Durect Corp NASDAQ:DRRX 1.010
0.040 (3.94%)
352034 0.95 - 1.03
13 Zecotek Photonics Inc TSXV:ZMS 0.290
0.010 (3.57%)
814376 0.28 - 0.29
14 Nymox Pharmaceutical Corp NASDAQ:NYMX 3.690
0.120 (3.36%)
254798 3.48 - 3.74
15 Merus Labs International Inc TSX:MSL 1.230
0.040 (3.36%)
49988 1.18 - 1.24
More